An in vivo investigative protocol for HDR prostate brachytherapy using urethral and rectal thermoluminescence dosimetry

Toye, Warren; Das, Ram Upendra; Kron, Tomas; Franich, Rick; Johnston, Peter; Duchesne, Gillian

doi:10.1016/j.radonc.2008.08.016

Cited by 35 publications

(18 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current methods for in vivo dosimetry are mainly based on the application of thermoluminescence detectors (TLDs) (Toye et al 2009) or semiconductor diodes (Waldhäusl et al 2005). TLDs involve offline process providing the integral dose absorbed during patient treatment and require special procedures in order to achieve good precision of the results.…”

Section: In Vivo Dosimetry In Radiotherapymentioning

confidence: 99%

Online in vivo dosimetry in high dose rate prostate brchytherapy with MOSkin detectors: In phantom feasibility study

Gambarini

Carrara

Tenconi

et al. 2014

Applied Radiation and Isotopes

View full text Add to dashboard Cite

MOSkin detectors were studied to perform real-time in vivo dose measurements in high dose rate prostate brachytherapy. Measurements were performed inside an urethral catheter in a gel phantom simulating a real prostate implant. Measured and expected doses were compared and the discrepancy was found to be within 8.9% and 3.8% for single MOSkin and dual-MOSkin configurations, respectively. Results show that dualMOSkin detectors can be profitably adopted in prostate brachytherapy treatments to perform real-time in vivo dosimetry inside the urethra. Highlights• A needles implant was set up in phantom to simulate prostate brachytherapy treatments• In vivo dosimetry was performed in the urethral catheter with MOSkin dosimeters• Dual-MOSkin detectors resulted to be accurate dosimeters to perform this task -2- AbstractMOSkin detectors were studied to perform real-time in vivo dose measurements in high dose rate prostate brachytherapy. Measurements were performed inside an urethral catheter in a gel phantom simulating a real prostate implant. Measured and expected doses were compared and the discrepancy was found to be within 8.9% and 3.8% for single MOSkin and dual-MOSkin configurations, respectively. Results show that dual-MOSkin detectors can be profitably adopted in prostate brachytherapy treatments to perform real-time in vivo dosimetry inside the urethra. KeywordsHigh dose rate, prostate brachytherapy , MOSFET, in vivo dosimetry -3-

show abstract

Section: In Vivo Dosimetry In Radiotherapymentioning

confidence: 99%

Online in vivo dosimetry in high dose rate prostate brchytherapy with MOSkin detectors: In phantom feasibility study

Gambarini

Carrara

Tenconi

et al. 2014

Applied Radiation and Isotopes

View full text Add to dashboard Cite

show abstract

“…A number of different systems to perform in vivo dosimetry have been developed, including passive integrating thermoluminescent dosimeters (TLDs) and active methods based on diodes, diamond detectors, optical fiber-coupled scintillators and MOSFETs (Fagerstrom et al, 2008;Rustgi, 1998;Toye et al, 2009;Waldhäusl et al, 2005;Zilio et al, 2006). Some of these have already been used to perform in vivo prostate dosimetry by directly placing them in either a needle in the prostate, a catheter in the urethra or in the rectum (Seymour et al, 2011;Suchowerska et al, 2011 .…”

Section: Trus-probe Integratedmentioning

confidence: 99%

TRUS-probe integrated MOSkin detectors for rectal wall in vivo dosimetry in HDR brachytherapy: In phantom feasibility study

Tenconi

Carrara

Borroni

et al. 2014

Radiation Measurements

View full text Add to dashboard Cite

The increasing complexity and high amount of dose per fraction delivered in prostate high dose rate (HDR) brachytherapy treatments call for the implementation of accurate and effective methods for the systematic and independent quality control of the overall treatment procedure. In this study, MOSkin detectors were placed on a trans-rectal ultrasound (TRUS) probe with the aim of performing both imaging and real time rectal wall in vivo dosimetry with the use of just one single instrument. After an adequate calibration of the detectors, which was carried out in a solid water phantom, the use of MOSkins integrated to the TRUS probe was studied in a gel phantom with a typical (simplified) prostate implant. Measured and calculated doses from the treatment planning system were compared, with a resulting very low average discrepancy of -0.6 ± 2.6%. The results are very promising and of particular clinical importance, however, further in vivo investigation is planned to validate the proposed method. Disciplines Engineering | Science and Technology Studies Publication DetailsTenconi, C., Carrara, M., Borroni, M., Cerrotta, A., Cutajar, D., Petasecca, M., Lerch, M., Bucci, J., Gambarini, G., Pignoli, E. & Rosenfeld, A. (2014). TRUS-probe integrated MOSkin detectors for rectal wall in vivo dosimetry in HDR brachytherapy: in phantom feasibility study. Radiation Measurements, 71 379-383. ABSTRACTThe increasing complexity and high amount of dose per fraction delivered in prostate high dose rate (HDR) brachytherapy treatments call for the implementation of accurate and effective methods for the systematic and independent quality control of the overall treatment procedure. In this study, MOSkin detectors were placed on a trans-rectal ultrasound (TRUS) probe with the aim of performing both imaging and real time rectal wall in vivo dosimetry with the use of just one single instrument.After an adequate calibration of the detectors, which was carried out in a solid water phantom, the use of MOSkins integrated to the TRUS probe was studied in a gel phantom with a typical (simplified) prostate implant. Measured and calculated doses from the treatment planning system were compared, with a resulting very low average discrepancy of 0.6 ± 2.6%. The results are very promising and of particular clinical importance, however, further in vivo investigation is planned to validate the proposed method.

show abstract

“…TLDs have given good results for HDR prostate brachytherapy IVD [8][9][10] but do not allow a real time measurement approach. Haughey et al [11] used a metal-oxide semiconductor field effect transistor (MOSFET) linear array inside the rectum during HDR prostate brachytherapy but concluded that the approach was not suitable due to the difficulties of quantifying uncertainties in MOSFET response.…”

Section: Introductionmentioning

confidence: 99%

Real-time in vivo dosimetry in high dose rate prostate brachytherapy

Mason¹,

Mamo²,

Al-Qaisieh³

et al. 2016

Radiotherapy and Oncology

View full text Add to dashboard Cite

Material and methods IVD was performed for 40 treatments planned using intra-operative trans-rectal ultrasound (TRUS) with a MOSFET inserted into an additional needle. Post-treatment TRUS images were acquired for 20 patients to assess needle movement. Monte Carlo simulations of treatment plans were performed for 10 patients to assess impact of heterogeneities.Per-needle and total plan uncertainties were estimated and retrospectively applied to the measured data as error detection thresholds. ResultsThe mean measured dose was -6.4% compared to prediction (range +5.1% to -15.2%). Needle movement and heterogeneities accounted for -1.8% and -1.6% of this difference respectively (mean values for the patients analysed). Total plan uncertainty (k=2) ranged from 11% to 17% and per needle uncertainty (k=2) ranged from 18% to 110% (mean 31%). One out of 40 plans and 5% of needles were outside k=2 error detection threshold. Conclusions

show abstract

An in vivo investigative protocol for HDR prostate brachytherapy using urethral and rectal thermoluminescence dosimetry

Cited by 35 publications

References 10 publications

Online in vivo dosimetry in high dose rate prostate brchytherapy with MOSkin detectors: In phantom feasibility study

Online in vivo dosimetry in high dose rate prostate brchytherapy with MOSkin detectors: In phantom feasibility study

TRUS-probe integrated MOSkin detectors for rectal wall in vivo dosimetry in HDR brachytherapy: In phantom feasibility study

Real-time in vivo dosimetry in high dose rate prostate brachytherapy

Contact Info

Product

Resources

About